

warfarin pharmacokinetics, 12:38

SMOKING

(See also SMOKE, TOBACCO;
SMOKE INHALATION; SMOK-
ING, CIGAR; SMOKING, PIPE;
SNUFF DIPPING; TOBACCO
CHEWING)

air pollution and chronic obstructive
lung disease and, 6:37

and air pollution in lung neoplasm
etiology, 5:25-27

allergy and, summary of findings,
1:23-24

antitrypsin deficiency and risk for
chronic obstructive lung disease,
6:33-34

bladder neoplasms and, summary of
findings, 1:17

bladder neoplasms in coal gas work-
ers and, 7:16

bronchitis and, summary of findings,
1:18

bronchopulmonary diseases and, sum-
mary of findings, 1:18-19

cardiovascular diseases and, summary
of findings, 1:13-15

chronic obstructive lung disease and,
6:7

chronic obstructive lung disease and
mortality, 6:9

coronary heart disease and, 4:21

effect of childhood respiratory symp-
toms on adult respiratory tract
disease, 6:38-39

effect of combined tobacco product
use on mortality ratio, 2:35-36,
2:39

effect on absenteeism, 3:8, 3:10

effect on absenteeism, summary of
findings, 1:12-13

effect on acrolein content in enclosed
spaces, 11:25

effect on activity limitation, 3:13-14

effect on angina pectoris, 4:47

effect on aryl hydrocarbon hydroxyl-
ase activity, 5:57

effect on asthmatic patients, 10:21-
22, 21:22

effect on benzo(a)pyrene content in
enclosed spaces, 11:24

effect on carbohydrate metabolism,
12:65

effect on carboxyhemoglobin levels,
15:29-30

effect on cardiovascular system,
12:15-16, 15:19

effect on catecholamine levels in
plasma, 14:88

effect on cause-specific mortality ra-
tio, 2:37-41

effect on central nervous system,
15:18-19

effect on cerebrovascular disease
risk, 4:50

effect on corticosteroid secretion,
12:40

effect on dimethylnitrosamine con-
tent in enclosed spaces, 11:25

effect on drug assays, 12:34

effect on enzyme activity, 1:25-26

effect on esophagus, 5:44, 13:25

effect on furosemide diuretic action,
12:54

effect on gastric secretion in man
and animals, 9:12

effect on gastric secretion in peptic
ulcer patients, 9:13-14

effect on hormones, 15:20

effect on imipramine pharmacokinet-
ics, 12:33

effect on immune system, 10:14-20

effect on immune system, summary
of findings, 1:18-19, 1:23-24, 1:26

effect on incidence of acute condi-
tions, 3:6, 3:9

effect on incidence of chronic condi-
tions, 3:6-7

effect on learning, 15:18-19

effect on levels of carbon monoxide
in expired air, 15:30

effect on lipid metabolism, 12:65

effect on lung function, 6:22

effect on lung function, summary of
findings, 1:18

effect on lung neoplasm histologic
type, 5:23-24

effect on lungs, summary of find-
ings, 1:18-19

effect on morbidity, 3:5

effect on morbidity, summary of
findings, 1:12-13

effect on mortality in the United
States, 2:9

effect on mortality in women, 2:25

effect on mortality ratios, summary of findings, 1:10-12
 effect on pancreatic secretion, 9:14-15
 effect on pesticide residue levels, 12:75
 effect on peptic ulcer healing and recurrence, 9:8-9
 effect on pharmacodynamics and pharmacokinetics, 12:27-44
 effect on pharmacodynamics and pharmacokinetics, summary of findings, 1:25-26
 effect on phenol red excretion, 12:39
 effect on protein binding of drugs, 12:40
 effect on protein metabolism, 12:65-66
 effect on pyloric pressure, 9:16
 effect on respiratory symptoms in children, 6:11-12
 effect on responses to diagnostic tests, summary of findings, 1:26
 effect on salivary secretory IgA levels, 10:17
 effect on secretin release, 9:15-16
 effect on sleep, 15:11
 effect on small airways function, 6:14-18
 effect on small airways pathology, 6:24, 6:27
 effect on vitamin B₆ levels, 12:67
 effect on vitamin B₁₂ levels, 12:66
 effect on vitamin C levels, 12:66
 emphysema and, 6:24-26
 emphysema and, summary of findings, 1:18-19
 esophageal neoplasms and, summary of findings, 1:17
 heredity and mortality and, 2:41
 interactive effect with occupational exposure, summary of findings, 1:19-20
 kidney neoplasms and, summary of findings, 1:17
 laryngeal neoplasms and, summary of findings, 1:16-17
 lung neoplasms and, summary of findings, 1:16
 lung pathology at autopsy in smokers vs. nonsmokers, 6:18
 methods for measuring usage, 15:29-31

myocardial infarct and, 4:21
 in myocardial infarct etiology, 4:38-40
 neoplasms and, summary of findings, 1:15-17
 and occupational exposure in lung neoplasm etiology, 27:29
 and occupational hazards recommendations for research, 7:19
 oral neoplasms and, summary of findings, 1:17
 pancreatic neoplasms and, summary of findings, 1:17
 peptic ulcer and, summary of findings, 1:23
 in peptic ulcer etiology, 9:11-12
 percent distribution of cigar, cigarette and pipe smokers in the United States, 13:9
 in polycythemia etiology, 12:83
 respiratory symptoms and, summary of findings, 1:18-19
 respiratory tract diseases in children and, 6:11
 as risk factor for chronic obstructive lung disease, research recommendations, 6:41-42
 as risk factor for bladder neoplasms after exposure to aromatic amines, 7:16
 standard conditions in the United States, 14:35
 in sudden cardiac death etiology, 4:44-45
 susceptibility to infections and, 10:19
 synergistic effect with uranium on respiratory tract, 12:90

SMOKING AND HEALTH
 Advisory Committee to the Surgeon General on Smoking and Health, historical perspective, 1-5-10
 effect of lifestyle, 3:11
 history of research, 1:5-10
 occupational hazards, 7:5

SMOKING, BIDIS
 leukoplakia and, 5:41

SMOKING CHARACTERISTICS
 adults in the United States 1964-1975, A:21-22
 effect of nicotine, 15:12
 effect on arsenic levels in the respiratory tract, 14:57
 effect on dependence, 14:97, 15:25

effect on nicotine absorption, 14:87
males vs. females, 5:21, 5:23
survey, respondent-reported styles,
A:21-22

research issues, A:22

SMOKING, CIGAR

(*See also* CIGARS; SMOKE, CIGAR; SMOKERS, CIGAR; TOBACCO, CIGAR)

bronchopulmonary diseases and, summary of findings, 1:28

in cardiovascular disease etiology, 13:32-34

cardiovascular diseases and, summary of findings, 1:28

in cerebrovascular disease etiology, 13:32-33

in chronic obstructive pulmonary disease etiology, 13:34-38

in coronary heart disease etiology, 13:32-33

effect of smoking duration on mortality ratio, 2:37

effect of smoking levels on lung neoplasm mortality, 13:27-28

effect of smoking levels on mortality, 13:14-17

effect of smoking levels on mortality ratio, 2:36-37

effect of use with other tobacco products on mortality ratio, 2:35-36, 2:39

effect on blood pressure, 13:34

effect on cholesterol levels in serum, 13:34

effect on laryngeal neoplasm mortality ratio, 13:24

effect on lung function, 13:34-35, 13:38

effect on lungs, 13:35

effect on mortality, 2:30, 2:35-37, 13:7-8, 13:13-14

effect on mortality rates, summary of findings, 1:27

effect on mortality ratios, 1:11-12

effect on neoplasm mortality ratios, 13:20

effect on oral neoplasm mortality ratios, 13:22

effect on pharyngeal neoplasm mortality ratios, 13:23

effect on respiratory symptoms, 13:36-37

emphysema and, 6:24-26

in lung neoplasm etiology, 13:28

NCSH survey in the United States, 13:8-9

neoplasms and, summary of findings, 1:27-28

nicotine absorption and, 13:17

oral neoplasms and, 5:39

peptic ulcer and, summary of findings, 1:28

in peptic ulcer etiology, 13:38

percent distribution in the United States, 13:9

SMOKING DURATION

age began smoking in males vs. females, 5:21, 5:23

bladder neoplasms and, 5:45

effect of age began smoking on lung neoplasm mortality ratio, 5:13-14

effect of age began smoking on mortality ratio, 2:19-21

effect on laryngeal neoplasm risk, 5:34

effect on lung neoplasm mortality ratio in women, 5:21-22

effect on mortality ratio, 2:17-19

effect on mortality ratio in cigar smokers, 2:37

effect on mortality ratio in ex-smokers, 2:28-29

effect on mortality ratio in pipe smokers, 2:38

effect on mortality ratio in women, 2:26-27

effect on myocardial infarct morbidity and mortality, 4:35

SMOKING HABIT

in blue- and white-collar workers, 7:17

carbon monoxide in maintenance, 15:15

carbon monoxide metabolism in maintenance, 15:17

central nervous system effects in establishment, 15:11

central nervous system effects in maintenance, 15:18

clinical importance in drug monitoring, 12:41-42

dependence in maintenance, 15:17-18
diurnal variations, 15:25-26

effect of β -blocker on cardiovascular system, 15:19

- effect of β -blocker on central nervous system, 15:18-19
- effect of β -blocker on hormones, 15:20
- effect of blood circulation on maintenance, 15:19-20
- effect of heredity, 15:9-10
- effect of hormones, 15:10
- effect of nicotine, 15:7-8
- effect of nicotine, summary of findings, 1:30-32
- effect of nicotine metabolism, 15:16
- effect of nicotine self-administration in animals, 15:11-12
- effect of tar, 15:7
- Index of General Psychological Well-Being and, 3:17-18
- lifestyle and, 3:11
- lung neoplasms, occupational risk and race differences, 7:17
- maintenance factors, 15:13
- maternal, personality and, 8:26-27
- nicotine in maintenance, 15:14
- pharmacological aspects, 15:5
- research issues, A:22
- role of carbon monoxide, 15:7
- summary of behavioral and psychosocial research, 1:32-33
- tar metabolism in maintenance, 15:17
- tobacco metabolism and, 15:9
- tobacco tars in maintenance, 15:15
- trends in males vs. females in the United States, 5:19-21
- women, 2:25-26, 5:19-21, 5:23
- SMOKING LEVELS**
(See also **CIGARETTE CONSUMPTION**)
- absteeism and, 3:10
- asbestos exposure and fibrosis, 7:13
- carboxyhemoglobin levels as indicator of self-reporting accuracy, 3:12
- chronic obstructive lung disease and, 6:7, 6:10
- effect on angina pectoris morbidity ratios, 4:43
- effect on aortic aneurysm mortality ratios, 4:55
- effect on atherosclerosis, 4:8-16
- effect on bladder neoplasm risk, 5:45
- effect on blood cholesterol levels, 4:62
- effect on body weight during pregnancy, 8:24
- effect on coronary heart disease morbidity ratios, 4:27-33, 4:36-37
- effect on coronary heart disease mortality ratios, 4:22-26, 4:36-37
- effect on intermittent claudication incidence, 4:53
- effect on kidney neoplasm mortality ratio, 5:49
- effect on laryngeal neoplasm risk, 5:33-36
- effect on leukocyte count, 12:79-82
- effect on life expectancy in the United States, 2:12
- effect on lung function, 6:22
- effect on lung neoplasm mortality in cigar and pipe smokers, 13:27-28
- effect on lung neoplasm mortality ratio in women, 5:21-22
- effect on lung neoplasm risk, 5:12-13, 5:16, 5:18-19
- effect on mortality ratio, 2:15-18, 5:13
- effect on mortality ratio in cigar and pipe smokers, 13:14-17
- effect on mortality ratio in cigar smokers, 2:36-37
- effect on mortality ratio in ex-smokers, 2:28-29
- effect on mortality ratio in pipe smokers, 2:36-38
- effect on mortality ratio in women, 2:26-27
- effect on myocardial infarct morbidity and mortality, 4:35-36
- effect on myocardial infarct risk in oral contraceptive users, 12:51-52
- effect on pancreatic neoplasm mortality and risk ratios, 5:50, 5:52
- effect on pancreatic secretion, 9:15
- effect on lung pathology, 6:27
- effect on peptic ulcer mortality rates, 9:11
- effect on placental ratio, 8:15-16, 8:18
- effect on serum vitamin B₁₂ levels in pregnant smokers vs. nonsmokers, 8:73
- effect on small airways function, 6:13-16
- effect on sudden cardiac death mortality ratios, 4:43
- emphysema and, 6:24-26

emphysema and radiation exposure and, 7:14
incidence of peptic ulcer and, 9:5
and lung pathology, 6:24
males vs. females, 5:21, 5:23
maternal, abruptio placentae, bleeding and placenta previa, 8:39
maternal, effect on birth weight, 8:12, 8:21, 8:25
maternal, effect on birth weight for gestational age, 8:20
maternal, effect on DDT content of breast milk, 8:51
maternal, effect on gestational age at birth, 8:43
maternal, effect on lactation, 8:50
maternal, effect on nicotine content of breast milk, 8:50
maternal, effect on perinatal mortality, 8:33
maternal, effect on perinatal mortality risk, 8:35
maternal, effect on weight gain and birth weight, 8:25
maternal, hyperkinesis in children and, 8:23
maternal, perinatal mortality and, 8:40
maternal, preeclampsia and toxemia and, 8:42
maternal, premature membrane rupture and, 8:39
maternal, sudden infant death syndrome and, 8:44-45
maternal, spontaneous abortion and, 8:30
maternal, synergism with other risk factors for perinatal mortality, 8:35
occupational exposure and health risk, 7:17
and pathological lesions of small airways, 6:18-19
prevalence of acute conditions and, 13:9
prevalence of chronic conditions and, 3:7
prevalence of peptic ulcer and, 9:6
respiratory symptoms and, 6:20
respiratory tract diseases in children and, 6:11
risk for respiratory tract infections and, 6:30

sex ratio in chronic obstructive pulmonary disease and, 6:20

SMOKING MACHINES

continuous vs. intermittent, 14:73
dosimetry, 14:74

SMOKING, MATERNAL

abortion and, 8:9, 8:30-32
abortion and, research needs, 8:77
abruptio placentae and stillbirth and, 8:39
anoxia and perinatal mortality and, 8:47
anteartum hemorrhage and, 8:39
bleeding during pregnancy and, 8:39
breast feeding and, 8:51
breast feeding and, research needs, 8:78-79
during pregnancy, and respiratory infection incidence in offspring, 11:32
effect of biologic factors on birth weight, 8:14-15
effect of smoking levels on birth weight, 8:12, 8:16
effect of smoking levels on placental ratio, 8:15, 8:18
effect of tobacco smoke on fetus and infant, mathematical model, 8:74
effect of socioeconomic factors on birth weight, 8:14-15
effect on behavioral development in children, 8:22
effect on behavioral, intellectual and physical development in children, 1:21
effect on bilirubin levels in neonate, 12:34
effect on birth weight, 8:9, 8:11-13, 8:17, 8:20-21, 8:26-27
effect on birth weight, research needs, 8:78
effect on birth weight, summary of findings, 1:21
effect on birth weight for gestational age, 8:19-20
effect on body height in children, 8:21-23
effect on body weight during pregnancy, 8:24
effect on body weight in children, 8:21-23
effect on breastfed infants, 8:51
effect on duration of gestation, 8:18

effect on fetal and neonatal mortality, 8:41
 effect on fetal breathing, 8:67
 effect on fetal growth, 8:12, 8:18-19
 effect on fetal growth, summary of findings, 1:21
 effect on fetal growth in animals, research needs, 8:78
 effect on fetal heart rate, 8:10, 8:67
 effect on fetal thermogram, 8:68
 effect on infant head and shoulder circumference, 8:19
 effect on infant mortality, 8:10, 8:28
 effect on intellectual development in children, 8:21-23
 effect on lactation, 8:48, 8:50
 effect on lactation, research needs, 8:78-79
 effect on lactation, summary of findings, 1:22
 effect on lymphocytotoxic antibodies, 10:18
 effect on maternal and fetal carboxyhemoglobin levels, 8:70
 effect on maternal weight gain and fetal growth, 8:24-25
 effect on nicotine content of breast milk, 8:50-51
 effect on neurological development in children, 8:21-22
 effect on oxygen availability in mother and fetus, 8:17
 effect on perinatal mortality, 8:32, 8:34-35
 effect on perinatal mortality, summary of findings, 1:22
 effect on physical development in children, 8:21-23
 effect on placenta, 8:69
 effect on placenta, research needs, 8:78
 effect on placental metabolism, 8:68-69
 effect on placental ratio, 8:14
 effect on pregnancy, 8:9-11
 effect on respiratory tract infection incidence in children, 10:12, 11:32
 effect on umbilical artery, 8:69
 effect on vitamin C levels in breast milk, 8:52
 in etiology of fetal mortality, 8:38
 in etiology of neonatal mortality, 8:38
 in etiology of perinatal mortality in low birth weight infants, 12:67
 hospital admission rates of children and, 11:33
 hyperkinesis in children and, 8:23
 hypotensive effect of thiocyanate levels, 8:42
 incidence of low birth weight and, 8:12
 long-term study of effects on children, research needs, 8:77
 neonatal mortality and, research needs, 8:76
 perinatal mortality risk and, 8:28
 personality characteristics and, 8:26
 placenta previa and, 8:39
 preeclampsia and, research needs, 8:77
 pregnancy complications and, research needs, 8:76-77
 premature membrane rupture and, 8:39
 prematurity and, 1:22
 preterm delivery and infant mortality risk, 8:42
 smoking levels and spontaneous abortion, 8:30
 spontaneous abortion and, 8:9, 8:30-32
 spontaneous abortion in wanted vs. unwanted pregnancy and, 8:30-32
 stillbirth and, 8:36-37
 sudden infant death syndrome and, 8:44-45
 sudden infant death syndrome and, research needs, 8:77

SMOKING, PARENTAL
(See also SMOKING, MATERNAL)
 effect on asthmatic children, 10:21
 effect on children, 11:31
 effect on respiratory tract infection incidence in children, 10:12
 effect on youth, 17:5, 17:13, 21:13-14
 maintenance of smoking and, 18:15
 prevalence of respiratory disease in children and, 11:32-34
 sudden infant death syndrome and, 8:45

SMOKING, PIPE
(See also SMOKE, PIPE; SMOKERS, PIPE; TOBACCO, PIPE)
 in bronchial neoplasm etiology, 13:28-29

- bronchopulmonary diseases and, summary of findings, 1:28
- cardiovascular diseases and, summary of findings, 1:28
- in cardiovascular disease etiology, 13:32-34
- in cerebrovascular disease etiology, 13:32-33
- in chronic obstructive pulmonary disease etiology, 13:34-38
- in coronary heart disease etiology, 13:32-33
- effect of smoking duration on mortality ratio, 2:38
- effect of smoking levels on lung neoplasm mortality, 13:27-28
- effect of smoking levels on mortality ratio, 2:36-38, 13:14-17
- effect of use with other tobacco products on mortality ratio, 2:35-36, 2:39
- effect on blood pressure, 13:34
- effect on cholesterol levels in serum, 13:34
- effect on lungs, 13:35
- effect on mortality, 1:11-12, 2:30, 2:35-37, 13:7-8, 13:13-14
- effect on mortality rates, summary of findings, 1:27
- effect on laryngeal neoplasm mortality ratios, 13:24
- effect on lung function, 13:34-35, 13:38
- effect on neoplasm mortality ratios, 13:20
- effect on oral neoplasm mortality ratios, 13:22
- effect on pharyngeal neoplasm mortality ratios, 13:23
- effect on respiratory symptoms, 13:36-37
- emphysema and, 6:24-26
- in ex-cigarette smokers, 19:29
- in lip neoplasm etiology, 13:21
- NCSH survey in the United States, 13:8-9
- neoplasms and, summary of findings, 1:27-28
- oral neoplasms and, 5:39
- peptic ulcer and, summary of findings, 1:28
- in peptic ulcer etiology, 13:38
- percent distribution in the United States, 13:9
- SMOKING PREVALENCE**
- adults in the United States, A:11, A:12-14
- Health Interview Survey data, A:13
- socioeconomic status and, A:15-16
- teenagers in the United States, A:13-14
- in white and black adults 1965-1976, A:15
- SMOKING SURVEYS**
- adults in the United States 1949-1978, A:8-10
- adults in the United States 1968-1974, A:18
- Health and Nutrition Examination Survey, 3:11-12
- Health Interview Survey, 3:8-18
- medical faculty of Dublin University College, 22:14
- National Clearinghouse for Smoking and Health, 3:11
- research design, 17:7
- smoking and work-loss and bed-disability days, 3:8-18
- teenagers in the United States 1968-1974, A:18
- SMOKING WITHDRAWAL STUDY CENTRE (TORONTO)**
- group cessation program, 19:11
- SNUFF**
- carbon monoxide as reinforcing agent, 15:7
- consumption in the United States, 14:13
- effect of manufacturing process, 14:30
- effect on mouth mucosa in women, 13:39-40
- in leukoplakia etiology, 13:40
- in oral neoplasm etiology, 13:39-40
- prevalence of use in the United States, 13:10, 13:39
- tobacco selection, processing and manufacture, 13:38-39
- SNUFF DIPPING**
- (See also **SMOKING**)
- health effects, summary of findings, 1:29
- SOCIAL FACTORS**
- effect on mortality, 2:42

SOCIOECONOMIC STATUS

- cessation of smoking and, 18:20-22
- recidivism and, 19:31
- smoking and chronic obstructive lung disease, 6:38
- smoking in adolescents and, 17:8
- smoking prevalence in adults and, A:15-16, 18:16

SOIL

- effect on metal levels in tobacco, 14:58
- effect on tobacco quality, 14:16

STANFORD HEART DISEASE PREVENTION PROGRAM

- effect on cessation of smoking, 19:15-16, 21:24-25

STILLBIRTH

- maternal smoking and, 8:36-37
- etiology of, in smokers vs. nonsmokers, 8:36-37
- maternal smoking and abruptio placentae and, 8:39
- in smokers vs. nonsmokers, 8:36

STIMULUS CONTROL TREATMENT

- modification of smoking behavior, 16:16, 19:20-21, 19:29

STRESS

- (*See also* ANXIETY)
- nicotine excretion and, 16:8

STROKE

- oral contraceptives and smoking and, 12:51
- smoking and, 4:50, 4:52

STRUCTURAL FORMULA

- carcinogenic polynuclear aromatic hydrocarbons, 14:53
- catechol, 14:56
- heterocyclic compound carcinogens, 14:55
- isoprenoids, 14:50
- maleic hydrazide, 14:62
- nicotine, 14:46
- nicotine metabolic pathway, 14:93
- nitrosamines, 14:46
- pesticides in cigarette smoke, 14:62
- pesticides in tobacco, 14:62
- phenol, 14:56
- tobacco alkaloids, 14:46, 14:95
- weakly acidic heterocyclic compounds in cigarette smoke, 14:56

STUDENTS, COLLEGE

- alcohol, marijuana, and tobacco use, 18:14

- health education opportunities, 21:9-11

- smoking habits, 22:18

SUBARACHNOID HEMORRHAGE

- effect of smoking and oral contraceptives on risk, 4:50, 4:60-61

SUDDEN CARDIAC DEATH

- coronary heart disease and, 4:41-43
- effect of smoking levels on mortality ratios, 4:43
- induced by cholesterol and ischemia in primates, 4:43
- research needs, 4:45
- risk factors, 4:43-44
- smokers vs. nonsmokers, 4:43-44
- smoking in etiology of, 4:44-45

SUDDEN INFANT DEATH SYNDROME

- effect of maternal smoking, 8:44-45
- maternal smoking levels and, 8:44-45
- research needs, 8:77

SULFUR COMPOUNDS

- levels in cigarette smoke, 14:40

SWEDISH TWIN REGISTRY

- mortality ratios in smokers, 2:42

SYSTEMATIC DESENSITIZATION

- modification of smoking behavior, 19:22

TAR CONTENT

- of cigarettes and health characteristics, 3:11
- decrease in modern cigarettes, A:19-20
- sales weighted average per cigarette 1954-1977, A:19

TARS, CIGAR

- carcinogenicity, 13:30-32
- in cigars, 14:44

TARS, CIGARETTE

- and beta radiation induced skin carcinoma in mice, 7:10
- determination in mainstream smoke, 14:43
- effect on mortality, 2:22
- effect on smoking habit, 15:7
- metabolism in maintenance of smoking habit, 15:17
- polynuclear aromatic hydrocarbons and, 14:52
- reduction, effect on lung neoplasm mortality ratio, 5:15-16

reduction in particulate phase cigarette smoke, 14:108
reduction methods, 14:110
sales weighted average delivery in the United States, 14:109
summary of constituents, 1:29-30

TARS, PIPE
carcinogenicity, 13:30-32

TARS, TOBACCO
(See also **PARTICULATE PHASE, CIGARETTE SMOKE; TARS, CIGAR; TARS, CIGARETTE; TARS, PIPE; TOTAL PARTICULATE MATTER**)
carcinogens, cocarcinogens and tumor promoters, 5:54-57
in maintenance of smoking habit, 15:15

TEACHERS
attitudes and smoking habits of coaches, 21:13
attitudes toward school smoking in principals, 23:14
attitudes toward smoking education, 21:12-13
health education certification requirements, 23:28-31
as role models, 17:15, 21:12-13, 23:11-12, 23:35-36
school smoking policies, 23:8-12
smoking habits, 23:35-36
training in adult education, 21:9
training in antismoking education, 17:19, 20:14, 20:17, 23:21, 23:31-35, 23:39
training in health education, 20:19-20, 21:11, 21:19-21

TEENAGERS
(See also **ADOLESCENTS**)
cigarette consumption patterns in the United States, A:23
female, increase in smoking prevalence, A:14
smoking prevalence data, A:13-14
smoking surveys in the United States 1968-1974, A:18

TEMPERATURE PROFILES
effect of cigarette composition and size, 14:35

TETRAHYDROCANNABINOL
(See also **CANNABIS**)
effect on enzyme activity, 12:42-43

THEOPHYLLINE
effect of methylcholanthrene on metabolism in rats, 12:32
pharmacokinetics in smokers vs. nonsmokers, 12:31-32

THERMAL ENERGY ANALYZER
in tobacco analysis, 14:9

THIOCYANATE LEVELS
(See also **CYANIDES**)
in clinical determination of smoking levels, 12:42
in plasma of smokers vs. nonsmokers, 7:7
maternal smoking and hypotensive effect, 8:42
monitoring in cessation studies, 19:7, 19:20, 19:28
in saliva of smokers vs. nonsmokers, 15:30
in urine of smokers vs. nonsmokers, 7:7

THROMBOANGIITIS OBLITERANS
(See also **THROMBOSIS**)
allergy and, 4:60
atherosclerosis and, 4:60
clinical and pathological features, 4:60
role of tobacco proteins in etiology of, 4:60
smoking and, 4:60

THROMBOEMBOLISM
oral contraceptives and smoking and, 12:51

THROMBOSIS
(See also **CARDIOVASCULAR DISEASES; CORONARY HEART DISEASE; THROMBOANGIITIS OBLITERANS**)
mortality rates in cigar and pipe smokers, 4:59
mortality rates in smokers vs. nonsmokers, 4:59
research needs, 4:59
smoking and, 4:59
smoking and oral contraceptives and, 4:59

TOBACCO
(See also **TOBACCO CHEWING; TOBACCO, CIGAR; TOBACCO, CIGARETTE; TOBACCO, PIPE**)
allergic effects on cardiovascular system, 10:22-23

allergy and, summary of findings, 1:23-24
in allergy etiology, 10:23-24
amine and nitrosamine content, 12:74
antigen, role in immunoglobulin disease entities, 10:7
antigenicity of, 10:9-10
blends in cigarette manufacturing, effect on smoke constituents, 14:29
carcinogenesis induction in animals, 5:53-54
carcinogenesis induction in animals, summary of methods, 5:29-30
constituents, in main- vs. sidestream smoke, 11:5-6
constituents, effect with occupational exposure on health, 7:7-9
consumption, historical trends in the United States, 1:5
immune hyperresponsiveness, 10:20
isoprenoid levels, 14:48-49
male vs. female consumption in the United States, 14:13
metabolism in smokers vs. nonsmokers, 15:9
pesticide residue reduction, 14:61
production by type in the United States 1964-1975, 14:12
radioelement levels, 14:60
stems, used in cigarette manufacturing in the United States, 14:13
types, components after aging, 14:21
types, production in the United States 1964-1975, 14:12
types and classes, 14:13-15
types used in smoking products, 14:14
usability index, 14:23
usage measuring techniques, 15:29-31
worldwide production levels, 14:11

TOBACCO ADDITIVES
effect on percent weight of products, 14:63
use in chewing tobacco and snuff, 13:39

TOBACCO AGING
effect on components of tobacco types, 14:21
effect on taste and aroma, 14:19
methods, 14:19

TOBACCO CHEWING
(See also **BETEL CHEWING**)
carbon monoxide as reinforcing agent, 15:7
consumption in the United States, 14:13
effect of manufacturing process, 14:30
health effects, summary of findings, 1:29
leukoplakia and, 5:41
in leukoplakia etiology, 13:40-41
nitrosamines and, 14:45
in oral neoplasm etiology, 13:40-41
oral neoplasms and, 5:39-40
prevalence in the United States, 13:10, 13:39
tobacco selection, processing and manufacture, 13:38-39

TOBACCO, CIGAR
(See also **CIGARS; SMOKE, CIGAR; SMOKERS, CIGAR; SMOKING, CIGAR**)
components after fermentation, 14:22
storage and fermentation, 14:19-20
U.S. government definition, 13:10

TOBACCO, CIGARETTE
(See also **CIGARETTES; SMOKE, CIGARETTE; SMOKERS; SMOKING**)
United States Government definition, 13:10

TOBACCO, PIPE
(See also **SMOKE, PIPE; SMOKERS, PIPE; SMOKING, PIPE**)
consumption in the United States, 14:13
effect of manufacturing process, 14:30
United States Government definition, 13:11

TOBACCO COMBUSTIBILITY
(See also **TOBACCO PYROLYSIS**)
growth conditions and, 14:16-17
precursors of smoke constituents with tumor activity and, 14:23

TOBACCO CONTAMINANTS
aflatoxin B₁, 14:22
pesticides, effect on smoking quality, 14:18
radioelements, 14:20-21

TOBACCO CULTURE
chemical conversions, 14:19-20

- effect on tobacco leaf components, 14:16-17
- effect on tobacco quality, 14:16
- harvesting and tobacco quality, 14:17-18
- methods for quality improvement, 14:17-18
- TOBACCO CURING**
 - effect on nitrosamine levels, 14:45
 - effect on polonium-210 content, 14:113
 - homogenized leaf curing, 14:19, 14:26
 - maleic hydrazide and, 14:47
 - methods, 14:19
 - nicotine reduction and, 14:108
 - tar reduction and, 14:108
- Tobacco extracts**
 - See* **TOBACCO LEAF EXTRACTS**
- TOBACCO INDUSTRY**
 - economic impacts, 21:18
- TOBACCO LEAF**
 - alkane content, 14:48
 - allergies in tobacco workers, 10:20
 - antigens, 10:11
 - characteristics, as "markers" for smoke delivery and composition, 14:22-23
 - characteristics, correlations with smoke constituents, 14:24
 - characteristics and biological response, 14:25
 - classes produced in the United States, 14:14
 - combustibility and growth conditions, 14:16-17
 - components, 14:16
 - components, effect of tobacco culture, 14:16-17
 - components, fraction-1-protein as food source, 14:28
 - components, modification, 14:30
 - effect of aging, 14:19
 - effect of cultivation conditions on smoking quality, 14:15-16
 - effect of curing, 14:19
 - effect of growth conditions on components, 14:16-17
 - effect of stalk position on components, 14:18, 14:20
 - effect of stalk position on quality, 14:17-18, 14:20
 - effect on mainstream smoke composition, 14:38
 - effect on smoke components, 14:11
 - "markers", and modification of biological effect, 14:23
 - nicotine levels, 14:45
 - nonvolatile nitrosamine levels, 14:45
 - physical and chemical characteristics affecting smoking quality, 14:14-16
 - relation of chemical components to smoking quality, 14:20
 - United States Government grading system, 14:14
- TOBACCO LEAF EXTRACTS**
 - in allergy desensitization injections, 10:13
 - antigenicity, 10:10
 - in carcinogenesis induction in animals, summary of methods, 5:29-30
 - skin test reactions in allergic vs. nonallergic children, 10:13
 - skin test reactions in asthmatic patients, 10:10
 - skin test reactions in smokers vs. nonsmokers, 10:13
- TOBACCO PROTEINS**
 - allergic and irritant reactions, 10:13
 - antigenicity, 10:11
 - effect on blood coagulation, 4:60
 - role in thromboangiitis obliterans etiology, 4:60
 - skin test reactions, 10:12
- TOBACCO PYROLYSIS**
 - (See also* **TOBACCO COMBUSTIBILITY***)*
 - aromatic hydrocarbon reduction and, 14:111
 - benzene levels and, 14:49
 - naphthalene levels and, 14:49
- Tobacco reconstituted**
 - See* **TOBACCO SHEET**
- TOBACCO SHEET**
 - carcinogenicity, 14:29
 - ciliotoxicity, 14:105
 - economic effect on industry, 14:27
 - effect on tobacco product manufacturing, 14:27
 - tar levels and, 14:44
 - technological advances, 14:9
 - in cigarette manufacturing in the United States, 14:13
 - in tobacco product manufacturing, 14:27

Tobacco smoke

See SMOKE, TOBACCO

TOBACCO SUBSTITUTES

ciliotoxicity, 14:105

smoking habit and, 15:8

TOBACCO TYPES

carboxylic acid levels, 14:57

in chewing tobacco, 13:39

in cigarette manufacturing in the

United States, 14:13, 14:14

production in the United States,

1964-1975, 14:12

tar levels, 14:44

TOBACCO WITHDRAWAL SYNDROME

degree of deprivation and, 15:27

dependence and, 15:24-25

severity in males vs. females, 15:28

summary of findings, 1:32

time course, 15:26

TOBACCO WORKERS

abortion, 8:9

allergic asthma, 10:21

allergies to tobacco leaf products,
10:20

contact dermatitis, 10:23

TOLERANCE

to carbon monoxide in maintenance
of smoking habit, 15:15

to cigarette smoke in smokers vs.
nonsmokers, 15:16-17

effect of smoke inhalation in dogs,
15:16

to tobacco in maintenance of smok-
ing habit, 15:13-15

TONGUE NEOPLASMS

(See also MOUTH NEOPLASMS)

alcohol consumption and smoking
and, 5:41

TOTAL PARTICULATE MATTER

(See also PARTICULATE PHASE,
CIGARETTE SMOKE; TARS, TO-
BACCO)

carcinogens, 14:65

effect of homogenized leaf curing,
14:27

levels in cigar smoke, 13:11

nicotine reduction, 14:108

tar levels, 14:44

TOXEMIA

maternal smoking levels and, 8:42

TRACHEA

(See also RESPIRATORY
SYSTEM)

effect of cigar smoke on cilia in
cats, 13:37

in smoke inhalation methodology,
14:74

TRACHEAL NEOPLASMS

(See also RESPIRATORY TRACT
NEOPLASMS)

in hamster offspring after nitrosa-
mine injection of lactating moth-
ers, 8:50

induced by nitrosamines in animals,
5:30

TRACHEOBRONCHIAL CLEARANCE

(See also MUCOCILIARY
SYSTEM)

effect of tobacco smoke in dogs,
10:15

TRYPTOPHAN METABOLISM

bladder neoplasms and, 5:47

smokers vs. nonsmokers, 12:67

TUMOR PROMOTERS

(See also CARCINOGENS; COCAR-
CINOGENS)

role in carcinogenesis, 5:54

in tobacco smoke gas phase, 5:54-55

in tobacco smoke particulate phase,
5:54-55, 5:57

TWINS

lung neoplasm mortality in smokers
vs. nonsmokers, 5:23

mortality ratio in smokers, 2:42

smoking habit and heredity, 15:9-10

ULCER, PEPTIC

cigar and pipe smoking and, summa-
ry of findings, 1:28

cigar and pipe smoking in etiology
of, 13:38

economic impact in the United
States, 9:17

effect of smoking on bile reflux,
9:16

effect of smoking on healing, 9:9

effect of smoking on mortality in
males, 9:10-11

effect of smoking on size, healing,
and recurrence, 9:8-9

epidemiology, 9:5

etiology, 9:11-12, 9:16-17

- healing in smokers vs. nonsmokers, 9:10
- incidence in the United States, 9:17
- mortality in cigar vs. cigarette vs. pipe smokers, 13:38
- mortality in smokers, 2:41
- prevalence in male and female smokers and nonsmokers, 9:6-7, 9:8, 9:17
- prevalence in Poland, 9:6
- prevalence ratios in six countries, 9:8
- role of nicotine in induction, 9:12-13
- smoking, coffee and alcohol consumption and, 9:6
- smoking and, summary of findings, 1:23
- smoking in etiology of, 9:11-12
- smoking levels and prevalence of, 9:6
- UNIVERSITY OF ILLINOIS ANTI-SMOKING EDUCATION STUDY**
 - description, 20:15-18
 - evaluation, 17:20, 20:11
 - teaching approaches, 23:26-27
- URANIUM**
 - and smoking in lung neoplasm etiology, 5:23
 - synergistic effect with smoking on respiratory tract, 12:90
- URETHANE**
 - in cigarette smoke, 14:41
- URINE**
 - acidity and nicotine excretion, 16:8
 - effect of pH on nicotine metabolism, 14:92-93
 - nicotine content as measure of tobacco usage, 15:29
- USABILITY INDEX**
 - tobacco leaf "markers" in development, 14:23
- VENTILATION RATE**
 - effect on eye irritation, 11:26-27
- VERBAL REPORTS**
 - (See also **SELF REPORTS**)
 - as measure of tobacco usage, 15:31
- Ventilatory function tests**
 - See **RESPIRATORY FUNCTION TESTS**)
- VETERANS ADMINISTRATION**
 - recommendations for smoking control by health professionals, 22:22-23
- Vital capacity measurements**
 - See **RESPIRATORY FUNCTION TESTS**
- VITAMIN B₆ LEVELS**
 - effect of smoking, 12:67
- VITAMIN B₁₂**
 - levels, effect of smoking, 12:66
 - levels in pregnant smokers vs. nonsmokers, 8:73
 - tobacco amblyopia and, 12:66
- VITAMIN C LEVELS**
 - in breast milk, effect of maternal smoking, 8:52
 - effect of nicotine in animals, 12:66
 - effect of smoking, 12:66
 - in pregnant smokers vs. nonsmokers, 8:74
 - in smokers vs. nonsmokers, 12:34, 12:66
- VITAMIN DEFICIENCY**
 - smoking in etiology of, 12:66-67
- WARFARIN**
 - effect of benzo(a)pyrene on pharmacokinetics in rats, 12:38
 - effect of smoking on metabolism, 12:55
 - pharmacokinetics in smokers vs. nonsmokers, 12:38
- WEIGHT GAIN**
 - and smoking cessation, 19:31
- WITHDRAWAL CLINICS**
 - (See also **CESSATION OF SMOKING**)
 - effectiveness, 19:10-12, 19:15
 - evaluation design, 19:33-34, 19:36
 - sponsored by voluntary agencies, 21:16
- WITHDRAWAL STATE**
 - and maintenance of nonsmoking, 19:31
 - neuroticism and, 18:9
 - recidivism and, 16:18
 - as reinforcer of smoking, 16:9-11
 - symptoms, 16:14
- WOMEN**
 - (See also **SEX RATIO**)
 - acute conditions in smokers vs. nonsmokers, 3:8
 - cigarette consumption patterns in the United States, A:23

effect of inhalation, smoking duration and smoking levels on mortality ratio, 2:26-27
effect of less hazardous cigarettes on mortality ratios, 2:23-24
effect of smoking on mortality, 2:25-27
laryngeal neoplasm risk in ex-smokers, 5:38
laryngeal neoplasm risk in smokers, 5:36
lung neoplasm mortality rates, 5:16-18, 5:20
lung neoplasm mortality ratio in smokers, 5:20-22
myocardial infarct in smokers vs. nonsmokers, 4:35-36, 12:52
severity of tobacco withdrawal syndrome, 15:28
smoking habit, 2:25-62, 5:19-21, 5:23
smoking prevalence, A:11, A:12-13, A:17-18

WOMEN'S CHRISTIAN TEMPERANCE UNION

antismoking campaign, 23:12-13

WOMEN'S MOVEMENT

influence on adolescent smoking, 18:16-17
influence on smoking habits, 17:13
and sex differences in cessation of smoking, 18:21

WORKPLACE PROGRAMS

antismoking campaigns, 7:18-19
coronary prevention programs, 22:16-17, 22:19
modification of smoking behavior, 19:9-10, 19:28-29

WORLD HEALTH ORGANIZATION

report on antismoking legislation, 21:18

YMCA

antismoking programs, 20:24

ZINC LEVELS

smokers vs. nonsmokers, 12:73